A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia

Inclusion Criteria: * Diagnosis of AML as defined by the World Health Organization (WHO) classification (Vardiman 2009) * Primary refractory AML (defined as a failure to achieve a CR or CRi after therapy with curative intent) or AML in first relapse * ECOG Performance status 0, 1 or 2 * Age \> 18 and \< 70 years * For patients presenting with primary refractory AML, \> 20% blasts on baseline bone marrow assessment * For patients presenting with relapsed AML, \> 5% blasts on baseline bone marrow assessment Exclusion Criteria: * An initial diagnosis of acute promyelocytic leukemia (as defined by French-American-British criteria (Bennett 1976)) * Secondary AML, defined as AML evolving from antecedent hematological disorder or prior exposure to leukemogenic therapy or agent * Clinically active CNS leukemia * Previously received a total cumulative dose of cytarabine \> 6g/m2 in the last 6 months * Previously received \> 1 induction regimen (Defined as 1 or 2 cycles of a drug or a drug combination administered as remission induction therapy)